IEX · Idex
50 filings
IEX 10-Q Quarterly Reports
Idex - 50 quarterly reports
IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.
- 8-K · Jan 28, 2016
- 8-K · Feb 3, 2016
- 8-K · Feb 10, 2016
- 10-K · Feb 19, 2016
- 8-K · Feb 19, 2016
- 8-K · Mar 18, 2016
- 8-K · Apr 12, 2016
- 8-K · Apr 19, 2016
- 10-Q · Apr 25, 2016
- 8-K · Apr 25, 2016
- 8-K · Jun 15, 2016
- 8-K · Jul 19, 2016
- 8-K · Jul 25, 2016
- 8-K · Jul 28, 2016
- 10-Q · Aug 1, 2016
- 8-K · Sep 2, 2016
- 8-K · Oct 18, 2016
- 8-K · Oct 21, 2016
- 10-Q · Oct 25, 2016
- 8-K · Nov 8, 2016
- 8-K · Jan 4, 2017
- 8-K · Jan 31, 2017
- 8-K · Feb 2, 2017
- 10-K · Feb 23, 2017
- 8-K · Feb 23, 2017
- 8-K/A · Mar 8, 2017
- 8-K · Apr 20, 2017
- 8-K · Apr 25, 2017
- 10-Q · Apr 26, 2017
- 8-K · Apr 27, 2017
- 8-K · Jul 26, 2017
- 10-Q · Jul 26, 2017
- 8-K · Jul 28, 2017
- 8-K · Oct 17, 2017
- 8-K · Oct 20, 2017
- 10-Q · Oct 23, 2017
- 8-K · Jan 2, 2018
- 8-K · Jan 30, 2018
- 8-K · Feb 2, 2018
- 10-K · Feb 22, 2018
- 8-K · Apr 30, 2018
- 8-K · Apr 30, 2018
- 10-Q · Apr 30, 2018
- 8-K · May 3, 2018
- 8-K · Jul 25, 2018
- 10-Q · Jul 25, 2018
- 8-K · Jul 30, 2018
- 8-K · Oct 24, 2018
- 10-Q · Oct 24, 2018
- 8-K · Jan 30, 2019
- 10-K · Feb 28, 2019
- 10-Q · Apr 26, 2019
- 8-K · Apr 26, 2019
- 8-K · May 14, 2019
- 8-K · Jun 4, 2019
- 8-K · Jun 18, 2019
- 10-Q · Jul 26, 2019
- 8-K · Jul 26, 2019
- 10-Q · Oct 30, 2019
- 8-K · Oct 30, 2019
- 8-K · Jan 30, 2020
- 10-K · Feb 21, 2020
- 8-K · Feb 26, 2020
- 8-K · Apr 24, 2020
- 10-Q · Apr 24, 2020
- 8-K · Apr 29, 2020
- 8-K · May 13, 2020
- 10-Q · Jul 24, 2020
- 8-K · Jul 24, 2020
- 8-K · Oct 28, 2020
- 8-K · Oct 28, 2020
- 10-Q · Oct 28, 2020
- 8-K · Jan 13, 2021
- 8-K · Feb 1, 2021
- 8-K · Feb 1, 2021
- 8-K · Feb 4, 2021
- 8-K/A · Feb 10, 2021
- 10-K · Feb 25, 2021
- 8-K · Feb 26, 2021
- 8-K · Apr 28, 2021
- 8-K · Apr 28, 2021
- 10-Q · Apr 28, 2021
- 8-K · May 10, 2021
- 8-K · May 14, 2021
- 8-K · May 18, 2021
- 8-K · May 28, 2021
- 8-K · Jun 17, 2021
- 8-K · Jun 21, 2021
- 8-K · Jul 2, 2021
- 8-K · Jul 28, 2021
- 10-Q · Jul 28, 2021
- 8-K · Aug 26, 2021
- 10-Q · Oct 27, 2021
- 8-K · Oct 27, 2021
- 8-K · Feb 2, 2022
- 8-K · Feb 8, 2022
- 10-K · Feb 24, 2022
- 8-K · Feb 28, 2022
- 10-Q · Apr 27, 2022
- 8-K · Apr 27, 2022
- 8-K · May 10, 2022
- 8-K · Jun 16, 2022
- 10-Q · Jul 27, 2022
- 8-K · Jul 27, 2022
- 8-K · Sep 13, 2022
- 8-K · Sep 22, 2022
- 8-K · Oct 26, 2022
- 10-Q · Oct 26, 2022
- 8-K · Nov 2, 2022
- 8-K · Nov 17, 2022
- 8-K · Nov 18, 2022
- 8-K · Dec 16, 2022
- 8-K · Feb 1, 2023
- 10-K · Feb 23, 2023
- 10-Q · Apr 27, 2023
- 8-K · Apr 27, 2023
- 8-K · May 31, 2023
- 8-K · Jun 14, 2023
- 10-Q · Jul 27, 2023
- 8-K · Jul 27, 2023
- 8-K · Aug 30, 2023
- 8-K · Aug 30, 2023
- 8-K · Oct 25, 2023
- 8-K · Oct 26, 2023
- 10-Q · Oct 26, 2023
- 8-K · Feb 7, 2024
- 10-K · Feb 22, 2024
- 10-Q · Apr 24, 2024
- 8-K · Apr 24, 2024
- 8-K · May 8, 2024
- 8-K · Jul 23, 2024
- 8-K · Aug 1, 2024
- 10-Q · Aug 1, 2024
- 8-K · Aug 8, 2024
- 8-K · Aug 21, 2024
- 8-K · Sep 5, 2024
- 10-Q · Oct 30, 2024
- 8-K · Oct 30, 2024
- 8-K · Feb 4, 2025
- 8-K · Feb 20, 2025
- 10-K · Feb 20, 2025
- 8-K · May 1, 2025
- 10-Q · May 1, 2025
- 8-K · May 12, 2025
- 8-K · May 21, 2025
- 10-Q · Jul 30, 2025
- 8-K · Jul 30, 2025
- 8-K · Sep 18, 2025
- 8-K · Oct 29, 2025
- 10-Q · Oct 29, 2025
- 8-K · Dec 4, 2025
- 8-K · Feb 4, 2026
- 8-K · Feb 9, 2026
- 10-K · Feb 19, 2026
- 8-K · Apr 29, 2026
- 10-Q · Apr 29, 2026
- 8-K · May 8, 2026
- 8-K · Jul 29, 2026
- 10-Q · Jul 29, 2026
- 8-K · Aug 17, 2026
- 8-K · Sep 3, 2026
- 8-K · Oct 28, 2026
- 10-Q · Oct 28, 2026
- 2026-Q3Oct 28, 2026
Idex Quarterly Report for Q3 Ended Sep 30, 2026
IDEX Corporation's Form 10-Q for the quarter ended September 30, 2026 reports third-quarter net sales of $951.7 million, up 8% on both a reported and organic basis versus $878.7 million a year earlier. Reported diluted EPS attributable to IDEX was $1.95, up 15% from $1.70, and adjusted diluted EPS was $2.33, up 15% from $2.03. Operating income rose to $208.0 million from $185.8 million, and gross margin was 45.1% versus 44.5%. For the nine months, net sales were $2,759.2 million, up 8%, and diluted EPS was $5.49 versus $4.70, with the company noting that IEEPA tariff refunds contributed $0.10 to nine-month diluted EPS. Growth was led by the Health & Science Technologies segment, where Q3 net sales rose 14% and Adjusted EBITDA rose 18%, driven by AI-related demand for data center power and semiconductor markets, as well as space and defense. Fluid & Metering Technologies sales rose 3% and Fire & Safety/Diversified Products sales rose 5% in the quarter. Operating cash flow for the nine months was $543.2 million, and free cash flow was $477.3 million, compared with $427.0 million a year earlier. The company repurchased $227.0 million of shares in the nine months and paid $160.7 million in dividends. Balance sheet and liquidity remain solid. Cash and cash equivalents were $602.1 million, total borrowings were $1,759.0 million, and the company entered a second amended and restated $800 million revolving credit agreement maturing September 2031. The company stated it was in compliance with its covenants, with a leverage ratio of 1.72 to 1 and an interest coverage ratio of 14.69 to 1. Fitch affirmed its BBB+ rating in September 2026.
- 2026-Q2Jul 29, 2026
Idex Quarterly Report for Q2 Ended Jun 30, 2026
IDEX Corporation's second-quarter 2026 results show net sales of $920.6 million for the three months ended June 30, 2026, up from $865.4 million, and net sales of $1,807.5 million for the six months, up from $1,679.7 million. Reported net income attributable to IDEX was $143.4 million for the quarter, versus $131.6 million a year earlier, and diluted EPS was $1.93 versus $1.74. The company attributes the increase mainly to organic sales growth of 5% in both periods, driven by higher volumes in the Health & Science Technologies segment, along with favorable foreign currency and acquisition contributions. Adjusted diluted EPS attributable to IDEX was $2.32 for the quarter, up from $2.07. IEEPA tariff refunds were a significant factor this quarter. The company collected substantially all anticipated refunds in Q2 2026, which reduced cost of sales by $22.0 million, partly offset by a $14.7 million reduction in net sales from expected customer rebates. Management says the net impact contributed an $0.08 benefit to EPS. Gross margin rose to 46.3% for the quarter from 45.3%, and operating income increased to $199.9 million from $187.9 million. Balance sheet and cash flow remained solid. Cash and cash equivalents were $621.3 million, borrowings were $1,866.9 million in total, and the Revolving Facility had $529.6 million of net availability. Operating cash flow for the six months was $303.7 million, and free cash flow was $263.0 million. The company returned $77.1 million through share repurchases and $53.9 million through dividends in the quarter, and $774.7 million of repurchase authorization remained at June 30, 2026.
- 2026-Q1Apr 29, 2026
Idex Quarterly Report for Q1 Ended Mar 31, 2026
IDEX Corporation reported first-quarter 2026 net sales of $886.9 million, up from $814.3 million a year earlier, with organic sales increasing 5% driven mainly by higher volumes in the Health & Science Technologies segment, particularly in AI-driven data center power and semiconductor markets, along with positive price across segments. Operating income rose to $172.4 million from $142.0 million, and diluted EPS attributable to IDEX was $1.61 versus $1.26. Adjusted diluted EPS, a non-GAAP measure reconciled in the filing, was $2.00 compared with $1.75. Gross margin declined to 44.9% from 45.3%, pressured by price/cost and unfavorable mix. Cash generation was steady: operating cash flow was $103.7 million and free cash flow was $86.0 million, compared with $91.4 million a year earlier. The company returned $76.3 million through share repurchases and $52.8 million in dividends. Borrowings rose to $1.88 billion, mainly from $100.0 million drawn under the $800.0 million Revolving Facility, which had $517.2 million of net availability at quarter-end. Cash and cash equivalents were $586.2 million, and the company remained in compliance with its debt covenants, with an interest coverage ratio of 13.85 to 1 and a leverage ratio of 1.93 to 1. The filing notes that tariffs enacted in 2025 and early 2026 had no material impact on results to date, and management expects to continue mitigating potential unfavorable effects. The quarter also included $7.4 million of restructuring expenses and asset impairments, including $4.8 million of impairments in the FMT segment, and a $3.7 million gain on a legal settlement. Remaining share repurchase authorization was $849.7 million at quarter-end.
- 2025-Q3Oct 29, 2025
Idex Quarterly Report for Q3 Ended Sep 30, 2025
IDEX Corporation's third-quarter 2025 Form 10-Q reports record reported net sales of $878.7 million for the three months ended September 30, 2025, up from $798.2 million a year earlier, with net income attributable to IDEX of $127.8 million and diluted EPS of $1.70 versus $1.57. For the nine months, net sales were $2.56 billion and diluted EPS was $4.70 versus $5.02. Management attributes the growth largely to the Mott Corporation acquisition, with organic sales up 5% in the quarter and 1% year to date, and reports adjusted diluted EPS of $2.03 for the quarter. Restructuring charges of $18.3 million for the nine months relate to a 2025 initiative expected to cost about $20 million in total, primarily severance. Profitability was mixed. Gross margin was 44.5% for the quarter and 45.0% year to date, and Adjusted EBITDA reached $239.8 million in the quarter versus $214.3 million. Interest expense rose to $16.5 million in the quarter from $10.3 million, reflecting debt used to finance Mott, and the effective tax rate increased to 25.1% largely due to the enactment of the One, Big, Beautiful Bill Act. Management describes order trends as range-bound and notes customer hesitation around larger orders. The balance sheet remained solid, with cash of $593.8 million, total borrowings of $1.91 billion, and total equity of $4.01 billion. Operating cash flow for the nine months was $470.9 million and free cash flow was $427.0 million. The company repurchased $175.0 million of stock during the period and its board authorized an additional $635.0 million in repurchases in September 2025, leaving $999.7 million available. Credit ratings were reaffirmed at BBB (S&P), Baa2 (Moody's) and BBB+ (Fitch), and the company was in compliance with its financial covenants.
- 2025-Q2Jul 30, 2025
Idex Quarterly Report for Q2 Ended Jun 30, 2025
IDEX Corporation's second-quarter 2025 Form 10-Q reports net sales of $865.4 million for the three months ended June 30, 2025, up 7% from $807.2 million a year earlier, with the filing noting organic sales increased 1%, driven by the Mott Corporation acquisition. Reported diluted EPS attributable to IDEX was $1.74, down 6% from $1.86, reflecting higher amortization and interest expense tied to the Mott financing; the filing states adjusted diluted EPS of $2.07 was relatively flat. For the six months, net sales were $1,679.7 million (up 4%), and diluted EPS was $3.00 versus $3.46, with restructuring expenses rising to $18.2 million from $2.4 million due to organizational changes and severance. Gross margin was 45.3% for the quarter, essentially flat versus 45.4%, as price/cost and productivity gains offset volume deleverage and unfavorable mix. Segment Adjusted EBITDA was $260.1 million for the quarter, and consolidated Adjusted EBITDA was $237.2 million. Operating cash flow was $267.4 million for the six months, down from $290.2 million, and free cash flow was $238.3 million. Cash and equivalents stood at $568.2 million, total borrowings at $1,857.9 million, and the company repurchased $100.0 million of stock in the first half of 2025. Subsequent to the quarter, IDEX acquired Micro-LAM, Inc. on July 29, 2025 for $90.0 million in cash plus a potential earnout of up to $12.0 million, funded with revolver borrowings. The filing also states the company was in compliance with its financial covenants, with an interest coverage ratio of 12.94 to 1 against a 3.0 to 1 minimum and a leverage ratio of 2.08 to 1 against a 3.50 to 1 maximum.
- 2025-Q1May 1, 2025
Idex Quarterly Report for Q1 Ended Mar 31, 2025
IDEX Corporation's first quarter 2025 Form 10-Q reports net sales of $814.3 million, up 2% from $800.5 million a year earlier, while organic sales decreased 1%, reflecting lower volumes in parts of Fluid & Metering Technologies and Health & Science Technologies, partly offset by targeted growth initiatives and price capture. Diluted EPS attributable to IDEX was $1.26 versus $1.60, and the filing states adjusted diluted EPS was $1.75, down 7%. Operating income fell to $142.0 million from $161.2 million, driven by $17.5 million of restructuring expenses and asset impairments (versus $1.1 million) tied to 2025 severance actions, and by higher interest expense of $16.1 million from debt used to fund the Mott acquisition. Gross margin improved to 45.3% from 44.6%. Cash generation weakened in the quarter. Operating cash flow was $105.7 million compared with $156.6 million, and free cash flow was $91.4 million compared with $136.6 million, largely due to higher inventory investment and interest payments. The company repurchased $50.0 million of stock and repaid $30.2 million on its Revolving Facility, leaving $249.0 million drawn and about $548.0 million of net availability. Cash and cash equivalents were $594.1 million at March 31, 2025, and the company reported compliance with its financial covenants, with an interest coverage ratio of 14.08 to 1 and a leverage ratio of 2.22 to 1. Management states it expects the potential impact of tariffs and trade policy changes to be largely mitigated by price increases and cost reductions, and says short-cycle order patterns have not been discernibly disrupted to date. The filing also notes that the company expects an additional $3.5 million to $7.5 million of restructuring charges for the remainder of 2025.
- 2024-Q3Oct 30, 2024
Idex Quarterly Report for Q3 Ended Sep 30, 2024
IDEX Corporation's Form 10-Q for the quarter ended September 30, 2024 shows third-quarter net sales of $798.2 million, up 1% from $793.4 million a year earlier, with organic net sales flat. Net income attributable to IDEX fell 43% to $119.1 million, and diluted EPS was $1.57 versus $2.75. The company attributes the softness largely to continued market headwinds in the Health & Science Technologies segment, which saw lower volumes, partly offset by price capture and productivity across segments. Adjusted EBITDA was $214.3 million versus $225.5 million, and adjusted diluted EPS was $1.90 versus $2.12. The prior-year quarter included a $93.8 million pre-tax gain on the sale of Micropump, which explains much of the decline in reported earnings. For the nine months, net sales were $2,405.9 million, down 3% from $2,485.0 million, and organic net sales decreased 3%. Diluted EPS was $5.02 versus $6.42. Operating cash flow was $495.5 million and free cash flow was $445.9 million, roughly flat with the prior year. The most significant event of the period was the September 5, 2024 acquisition of Mott Corporation for cash consideration of $986.2 million, funded with cash on hand, $279.3 million of Revolving Facility borrowings, and $495.0 million of net proceeds from new 4.950% Senior Notes due 2029. Total borrowings rose to $2,087.4 million from $1,333.3 million at year-end 2023. Liquidity remains solid, with $633.2 million of cash and cash equivalents, $436.7 million of available Revolving Facility capacity, and compliance with financial covenants (interest coverage of 18.19 to 1 versus a 3.0 to 1 minimum, and leverage of 2.39 to 1 versus a 3.50 to 1 maximum). Subsequent to quarter end, the company repaid $69.1 million under the Revolving Facility and the remaining $25.0 million under the Term Facility. Credit ratings were reaffirmed by S&P (BBB, stable), Moody's (Baa2, stable) and Fitch (BBB+, stable).
- 2024-Q2Aug 1, 2024
Idex Quarterly Report for Q2 Ended Jun 30, 2024
IDEX Corporation reported second-quarter 2024 net sales of $807.2 million, down 5% from $846.2 million a year earlier, with organic net sales down 4%. The decline reflected lower volumes, largely in the Health & Science Technologies segment, partly offset by price capture and strong price/cost and productivity across segments. Net income attributable to IDEX rose 2% to $141.3 million, and diluted EPS increased to $1.86 from $1.82. Adjusted net income attributable to IDEX fell 6% to $156.1 million, and Adjusted EBITDA declined 7% to $224.2 million, with the Adjusted EBITDA margin at 27.8% versus 28.4%. Gross margin improved to 45.4% from 44.7%, and operating income fell 9% to $182.7 million. For the first half of 2024, net sales were $1,607.7 million, down 5%, and net income attributable to IDEX was $262.7 million. Cash flow from operations was $290.2 million, and free cash flow was $254.3 million. Cash and cash equivalents totaled $700.7 million at June 30, 2024, and the Revolving Facility had $719.2 million of net availability. The company paid $100.7 million in dividends during the six months and made no share repurchases, leaving $539.7 million of authorization remaining. The company was in compliance with its financial covenants at June 30, 2024. Looking ahead, IDEX entered into a definitive agreement on July 23, 2024 to acquire Mott Corporation for $1.0 billion in cash, expected to close by the end of the third quarter of 2024 subject to regulatory approvals. The acquisition is expected to be funded with cash on hand, borrowings under the Revolving Credit Facility and potential debt issuance. The company also acquired Subterra AI, Inc. for $7.5 million on July 25, 2024.
- 2024-Q1Apr 24, 2024
Idex Quarterly Report for Q1 Ended Mar 31, 2024
IDEX Corporation reported first-quarter 2024 net sales of $800.5 million, down from $845.4 million in the prior-year quarter, with organic net sales declining 6% as lower volumes in the Health & Science Technologies segment offset price capture across all segments. Net income attributable to IDEX was $121.4 million, or $1.60 diluted EPS, compared with $139.8 million and $1.84 a year earlier. Gross margin fell to 44.6% from 45.2%, and operating income declined to $161.2 million from $192.3 million, with the filing citing lower volume leverage and higher employee-related costs. Adjusted diluted EPS was $1.88 versus $2.09, per the company's non-GAAP reconciliation. Cash generation remained solid. Cash flows from operating activities rose to $156.6 million from $147.9 million, driven mainly by lower cash payments for variable compensation, and free cash flow was $136.6 million versus $121.3 million. Cash and cash equivalents increased to $616.3 million at March 31, 2024, while total borrowings were $1,330.9 million and the Revolving Facility had $717.8 million of net availability. The company made no share repurchases during the quarter, leaving $539.7 million of authorization remaining, and paid $48.5 million in dividends. The Health & Science Technologies segment was the main source of weakness, with net sales down 12% and Adjusted EBITDA down 19%, attributed to inventory recalibration and market slowness in analytical instrumentation, life sciences and semiconductor markets. Fluid & Metering Technologies sales declined 3%, while Fire & Safety/Diversified Products grew 2%. The company stated it expects no material impact from the OECD Pillar Two global minimum tax rules.
- 2023-Q3Oct 26, 2023
Idex Quarterly Report for Q3 Ended Sep 30, 2023
IDEX Corporation's Form 10-Q for the quarter ended September 30, 2023 shows third-quarter net sales of $793.4 million, down from $824.0 million a year earlier, while net income attributable to IDEX rose to $209.1 million from $178.7 million. The filing attributes the net sales decline to lower volumes in the Health & Science Technologies segment, where customer inventory recalibration reduced demand, partially offset by price capture across all segments. Net income was boosted by a pre-tax gain of $93.8 million on the sale of the Micropump business, which the filing says contributed a $71.1 million gain, net of tax. Diluted EPS was $2.75 versus $2.36, while adjusted diluted EPS was $2.12 versus $2.14 as reported in the filing's non-GAAP reconciliation. For the nine months, net sales rose to $2,485.0 million from $2,371.2 million and net income attributable to IDEX reached $487.5 million versus $456.9 million. Cash flow from operating activities was $515.7 million for the nine months, compared with $390.1 million a year earlier, and free cash flow was $447.4 million versus $342.1 million. The company reported cash and cash equivalents of $562.7 million, total borrowings of $1,329.4 million, and repaid $150.0 million of its Term Facility during the quarter. Management said it believes customer destocking efforts are largely complete and expects orders to stabilize and lead times to normalize during the fourth quarter of 2023. The filing notes an interim gross margin of 44.1% for the quarter versus 46.3% a year earlier, and an adjusted EBITDA of $225.5 million versus $231.4 million. Covenant compliance was reported, with an interest coverage ratio of 18.62 to 1 and a leverage ratio of 1.42 to 1 against required levels of 3.0 to 1 and 3.50 to 1, respectively.
- 2023-Q2Jul 27, 2023
Idex Quarterly Report for Q2 Ended Jun 30, 2023
IDEX Corporation reported record second-quarter 2023 net sales of $846.2 million, up 6% from $796.1 million a year earlier, with organic net sales growth of 3%. Net income attributable to IDEX was $138.6 million, compared with $138.2 million, and diluted EPS was $1.82, up 1%. Adjusted diluted EPS rose 8% to $2.18, and Adjusted EBITDA increased 10% to $240.7 million, a 28.4% margin. For the six months, net sales were $1,691.6 million, up 9%, and operating cash flow was $289.1 million, compared with $192.0 million a year earlier. Free cash flow was $240.9 million, which the filing attributes mainly to lower investments in working capital. Segment performance was mixed. Fluid & Metering Technologies and Fire & Safety/Diversified Products grew, while Health & Science Technologies was challenged by customer inventory recalibration in the Analytical Instrumentation, Life Science and Biopharma markets, and its second-quarter Adjusted EBITDA fell 10% to $93.7 million. Management expects revenues and earnings in the second half of 2023 to be lower than in the first half, driven by market-based declines in both the FMT and HST segments. During the period, IDEX acquired Iridian for $110.3 million in cash and recorded a $7.7 million credit loss on a note receivable from a collaborative partner. It also issued $100 million of 5.13% Senior Notes due 2028 and used the proceeds to repay the 3.20% Senior Notes due June 2023. At June 30, 2023, cash and cash equivalents were $457.0 million and total borrowings were $1,480.5 million. The company stated it was in compliance with its financial covenants, with a leverage ratio of 1.52 to 1 and an interest coverage ratio of 21.03 to 1.
- 2023-Q1Apr 27, 2023
Idex Quarterly Report for Q1 Ended Mar 31, 2023
IDEX Corporation's Form 10-Q for the quarter ended March 31, 2023 reports net sales of $845.4 million, up 13% from $751.1 million a year earlier, with organic sales up 6%. Net income attributable to IDEX was $139.8 million, essentially flat versus $140.0 million, and diluted EPS rose to $1.84 from $1.83. The filing states adjusted diluted EPS of $2.09, up $0.13 or 7%, and Adjusted EBITDA of $229.8 million, up 7%, with the Adjusted EBITDA margin of 27.2% down 140 basis points. Net sales growth was driven by acquisitions (Muon Group, KZValve, Nexsight), partly offset by a 2% unfavorable foreign currency impact. Operating income rose to $192.3 million from $187.6 million, while interest expense increased to $13.1 million from $9.5 million, reflecting borrowings used for the Muon Group acquisition. Cash flow strengthened considerably. Operating cash flow was $147.9 million, up from $79.7 million, mainly due to lower working capital investment. Free cash flow was $121.3 million, compared with $63.6 million in the prior year. Cash and cash equivalents rose to $510.7 million at March 31, 2023. Total borrowings were $1,479.5 million, and the company stated it was in compliance with its financial covenants. No share repurchases occurred in the quarter, and $563.8 million remained under the authorization. Subsequent to quarter end, on April 25, 2023, IDEX agreed to acquire Iridian Spectral Technologies for cash consideration of 150.0 million Canadian dollars, with closing expected by the end of the second quarter of 2023. The filing also notes that the 3.20% Senior Notes due June 2023 ($100.0 million) are expected to be refinanced or repaid using the Revolving Credit Facility.
- 2022-Q3Oct 26, 2022
Idex Quarterly Report for Q3 Ended Sep 30, 2022
IDEX Corporation's Form 10-Q for the quarter ended September 30, 2022 reports record nine-month sales of $2.37 billion, up 16%, with organic sales up 13%. Third-quarter net sales were $824.0 million, up 16%, and operating income rose 25% to $202.2 million, with operating margin of 24.5%. Net income attributable to IDEX was $178.7 million for the quarter (up 54%) and $456.9 million for the nine months (up 38%). Diluted EPS was $2.36 for the quarter and $6.00 for the nine months. The company also reported adjusted diluted EPS of $2.14 for the quarter and $6.12 for the nine months, both non-GAAP measures. The quarter included a $34.8 million pre-tax gain on the sale of the Knight business and a $17.9 million acceleration of previously deferred revenue, along with a $16.8 million impairment, tied to a customer's decision to discontinue a COVID-19 testing application. Cash flow from operations for the nine months was $390.1 million, down from $402.2 million, as working capital increased. Operating working capital rose $116.8 million to $664.8 million, and free cash flow was $342.1 million. Cash and equivalents stood at $680.7 million at quarter end, and total borrowings were $1,200.1 million, all fixed-rate. Subsequent to the quarter, IDEX agreed on September 13, 2022 to acquire Muon Group for €700.0 million in cash, expected to close by the end of 2022. The company plans to fund it with $350.0 million of cash on hand, $150.0 million from its revolving facility, and $200.0 million from a new debt issuance. The company repurchased 788,623 shares for $146.8 million during the first nine months and retains $565.2 million of repurchase authorization.
- 2022-Q2Jul 27, 2022
Idex Quarterly Report for Q2 Ended Jun 30, 2022
IDEX Corporation's second-quarter 2022 results show record six-month sales of $1.55 billion, up 16% from $1.34 billion a year earlier, with organic sales up 12%. Operating income rose 18% to $186.6 million for the quarter, and operating margin expanded 30 basis points to 23.4%. Net income attributable to IDEX increased 35% to $138.2 million for the quarter, and diluted EPS reached $1.81 versus $1.34. For the six months, diluted EPS was $3.65, up $0.84 or 30%. Adjusted EPS for the quarter was $2.02, up 15%. Growth was driven by acquisitions and organic demand. Organic sales rose 12% in the quarter, with acquisitions contributing 7% and foreign currency reducing sales by 3%. The company completed the Nexsight acquisition for $114.7 million and the KZValve acquisition for $120.2 million, both funded with cash on hand. Operating cash flow fell to $192.0 million for the six months from $245.6 million, primarily due to higher working capital, and free cash flow was $160.3 million. Inventories rose to $457.4 million from $370.4 million at year-end 2021 to support production amid supply chain difficulties. The balance sheet remains conservative. Cash and cash equivalents were $557.8 million, total borrowings were $1,200.1 million, all at fixed rates, and the company had $792.8 million of net available revolver capacity. The company repurchased 622,190 shares for $115.8 million in the first half, leaving $596.2 million of authorization, and paid $86.9 million in dividends. The company stated it was in compliance with its financial covenants, with an interest coverage ratio of 23.38 to 1 and a leverage ratio of 1.40 to 1.
- 2022-Q1Apr 27, 2022
Idex Quarterly Report for Q1 Ended Mar 31, 2022
IDEX Corporation's Form 10-Q for the quarter ended March 31, 2022 reports a record quarter in sales, operating margin and earnings per share. Net sales were $751.1 million, up 15% from $652.0 million, with organic sales up 12%. Operating income rose 21% to $187.6 million, and operating margin was 25.0%, up 110 basis points. Net income attributable to IDEX was $140.0 million, up 24%, and diluted EPS was $1.83, compared with $1.48 a year earlier. Adjusted diluted EPS was $1.96. Management attributed the results to robust demand and strong price capture amid inflation, along with operational productivity, while noting material availability and logistical challenges. Cash generation weakened. Operating cash flow fell to $79.7 million from $109.3 million, mainly because of higher working capital, and free cash flow was $63.6 million versus $94.7 million. Operating working capital rose $81.5 million to $629.5 million, with inventories up to support production amid supply chain difficulties. The company spent $114.7 million on the Nexsight acquisition, repurchased 147,500 shares for $28.3 million, and paid $41.4 million in dividends. Cash and cash equivalents stood at $733.2 million, and total borrowings were $1,200.1 million, all fixed-rate. Covenant compliance was reported, with an interest coverage ratio of 21.68 to 1 and a leverage ratio of 1.46 to 1. Looking ahead, the company agreed on March 30, 2022 to acquire KZ CO. (KZValve) for $120.0 million in cash, a business with annual sales of about $28.0 million that it expects to close by the end of the second quarter of 2022, subject to regulatory approval. The filing also reports credit ratings of BBB (S&P), Baa2 (Moody's) and BBB+ (Fitch), all with stable outlooks.
- 2021-Q3Oct 27, 2021
Idex Quarterly Report for Q3 Ended Sep 30, 2021
IDEX Corporation reported third-quarter 2021 net sales of $712.0 million, up 23% from the prior year, with organic sales up 15%. Operating income rose 23% to $161.2 million, and adjusted operating income increased 29% to $173.1 million. Net income attributable to IDEX grew 11% to $115.7 million, and diluted EPS was $1.51, up 10%. Adjusted EPS was $1.63, up 16%. For the first nine months, net sales were $2,050.0 million, up 18% (organic up 12%), and diluted EPS was $4.33, up 19%. Growth was supported by acquisitions. ABEL Pumps was acquired in March 2021 for $106.3 million and Airtech Group in June 2021 for $471.0 million, both funded with cash on hand. Health & Science Technologies was the strongest segment, with third-quarter sales up 37% and operating margin of 23.3%. Operating cash flow for the nine months was $402.2 million, down 1% on unfavorable working capital changes, and free cash flow was $356.7 million. The balance sheet remains solid. Cash and cash equivalents were $806.5 million and total borrowings were $1,200.1 million, all fixed rate. In May 2021 the company issued $500.0 million of 2.625% Senior Notes due 2031 and used the proceeds to redeem $350.0 million of 4.20% Senior Notes, which produced an $8.6 million loss on early debt redemption. The company also recorded a $9.7 million noncash loss from terminating the U.S. pension plan. No shares were repurchased in the first nine months of 2021, and $712.0 million remained under repurchase authorizations.
- 2021-Q2Jul 28, 2021
Idex Quarterly Report for Q2 Ended Jun 30, 2021
IDEX Corporation's second-quarter 2021 Form 10-Q reports net sales of $685.9 million for the three months ended June 30, 2021, up 22% from $561.2 million a year earlier, with organic sales up 17%. Operating income rose to $158.3 million (23.1% operating margin) from $110.6 million, and net income attributable to IDEX was $102.2 million, or $1.34 diluted EPS, versus $0.93 in the prior-year quarter. For the six months, net sales were $1.34 billion (up 16%) and diluted EPS was $2.81. Results were helped by higher volume and price capture, partially offset by inflation, supply chain constraints and a $3.9 million Corporate transaction indemnity reserve; other expense included a $9.7 million noncash loss from terminating the U.S. pension plan and an $8.6 million loss on early debt redemption. The balance sheet expanded materially through acquisitions. IDEX acquired Airtech for $469.3 million in cash on June 14, 2021, and ABEL Pumps for $106.3 million on March 10, 2021, both funded with cash on hand. Goodwill rose to $2.21 billion and intangible assets to $626.6 million, while cash fell to $714.4 million from $1,025.8 million at year-end 2020. Total borrowings were $1.20 billion, and the company issued $500.0 million of 2.625% Senior Notes due 2031 to redeem $350.0 million of 4.2% Senior Notes. The company reported no share repurchases in the first six months of 2021 and $712.0 million remaining under its repurchase authorization. Cash flow from operations was $245.6 million for the six months, down from $254.2 million, mainly because of working capital increases and timing of tax payments. Free cash flow, a non-GAAP measure defined as operating cash flow minus capital expenditures, was $215.0 million. Management stated that it expects sufficient cash and capital access to fund operations for at least the next twelve months.
- 2021-Q1Apr 28, 2021
Idex Quarterly Report for Q1 Ended Mar 31, 2021
IDEX Corporation's first-quarter 2021 Form 10-Q reports net sales of $652.0 million, up 10% from $594.5 million in the first quarter of 2020, with organic sales up 6%, acquisitions contributing about 1%, and a 3% favorable impact from foreign currency translation. Operating income rose to $155.5 million (operating margin 23.9% versus 23.5%), and net income attributable to IDEX was $112.7 million, or $1.48 per diluted share versus $1.33 a year earlier. The company reported adjusted diluted EPS of $1.51 after excluding $2.2 million of restructuring expenses and asset impairments and a $0.7 million fair value inventory step-up charge. Operating cash flow was $109.3 million, and free cash flow was $94.7 million. Cash and cash equivalents were $958.1 million at March 31, 2021, with no balance outstanding under the $800 million Revolving Facility and $792.9 million of net available borrowing capacity. The quarter's main event was the March 10, 2021 acquisition of ABEL Pumps for $106.2 million in cash, which added $59.0 million of goodwill and $46.0 million of intangible assets to the Pumps reporting unit. Subsequent to quarter end, on April 27, 2021, IDEX agreed to acquire Airtech Group and US Valve Corporation from EagleTree Capital for $470.0 million in cash, with closing expected by the end of the second quarter of 2021. Total debt was $1,050.2 million, all fixed rate, and the company reported compliance with its financial covenants, including a 15.28 to 1 interest coverage ratio and a 1.60 to 1 leverage ratio. Segment results were mixed. Health & Science Technologies delivered the strongest growth, with sales up 12% and operating income up to $66.7 million from $52.6 million. Fluid & Metering Technologies sales rose 7%, but its operating income fell to $62.9 million from $66.8 million, reflecting inventory reserves tied to COVID-19 new product development opportunities that did not materialize. Fire & Safety/Diversified Products sales increased 11%, and operating income rose to $44.6 million. Management said end markets improved from the third quarter of 2020 through the first quarter of 2021 and expects them to normalize to historical levels throughout 2021, while cautioning that the continuing effects of COVID-19 cannot be predicted.
- 2020-Q3Oct 28, 2020
Idex Quarterly Report for Q3 Ended Sep 30, 2020
IDEX Corporation's Form 10-Q for the quarter ended September 30, 2020 reports third-quarter net sales of $581.1 million, down 7% from $624.2 million a year earlier, with organic sales down 12%. Operating income was $131.2 million (22.6% margin) and net income was $103.8 million, with diluted EPS of $1.37, flat year over year. For the nine months, net sales were $1,736.8 million (down 8%), operating income was $381.7 million (down 14%), and net income was $276.7 million (down 16%). The filing attributes the declines primarily to lower volume tied to the COVID-19 pandemic, partially offset by price, restructuring savings and tighter discretionary spending. Management expects fourth-quarter organic sales to be down approximately 3 to 5 percent. The balance sheet strengthened in liquidity terms. Cash and cash equivalents rose to $877.8 million from $632.6 million at year-end 2019, and the company reports over $1.6 billion of liquidity and gross leverage of 1.7 times. Total borrowings were $1,050.3 million, almost entirely fixed-rate, after the company issued $500.0 million of 3.0% Senior Notes due 2030 in April 2020 and used the proceeds to redeem $300.0 million of 4.5% Senior Notes, incurring an $8.4 million loss on early debt redemption. Operating cash flow for the nine months was $407.9 million, and free cash flow was $368.5 million. Shareholders' equity increased to $2,396.5 million. Capital deployment during the period included the Flow MD acquisition for $118.2 million in cash, dividends paid of $114.2 million, and share repurchases of $110.3 million. The company had $712.0 million of remaining repurchase authorization at September 30, 2020. Management reported that its covenant compliance was intact, with an interest coverage ratio of 14.60 to 1 and a leverage ratio of 1.7 to 1 against required limits of 3.00 and 3.50.
- 2020-Q2Jul 24, 2020
Idex Quarterly Report for Q2 Ended Jun 30, 2020
IDEX Corporation's Form 10-Q for the quarter ended June 30, 2020 shows second-quarter net sales of $561.2 million, down 13% from $642.1 million a year earlier, with organic sales down 17% as COVID-19 weighed on demand across all three segments. Operating income fell to $110.6 million (19.7% operating margin versus 24.2%), and net income was $70.9 million, or $0.93 diluted EPS, compared with $113.2 million and $1.48 a year earlier. Adjusted diluted EPS was $1.10 for the quarter, excluding restructuring, a fair value inventory step-up charge and a loss on early debt redemption. For the first half, net sales were $1,155.7 million and net income $172.9 million, with diluted EPS of $2.27. The balance sheet strengthened in liquidity terms. Cash and cash equivalents rose to $746.3 million at June 30, 2020, from $632.6 million at December 31, 2019. In April 2020 the company issued $500.0 million of 3.0% Senior Notes due 2030 and used the proceeds to redeem $300.0 million of 4.5% Senior Notes, which produced an $8.4 million loss on early debt redemption. Total borrowings were $1,050.4 million, and the company reported $792.9 million of net available capacity under its Revolving Facility. Operating cash flow for the first six months was $254.2 million, and the company repurchased $110.3 million of stock while paying $76.5 million in dividends. Management expects the third quarter of 2020 to remain challenging, anticipating organic sales declines of approximately 12 to 17 percent. The company completed the Flow MD acquisition in February 2020 for $120.8 million cash, and it formed a joint venture in Saudi Arabia that is expected to be consolidated once funded in the third quarter of 2020. The company reports $1.5 billion of liquidity and gross leverage of 1.6 times.
- 2020-Q1Apr 24, 2020
Idex Quarterly Report for Q1 Ended Mar 31, 2020
IDEX Corporation's Form 10-Q for the quarter ended March 31, 2020 shows first-quarter net sales of $594.5 million, down 4% from $622.2 million a year earlier, with organic sales down 5% and a 2% contribution from acquisitions. Operating income fell to $139.9 million (23.5% operating margin versus 23.8%), and net income decreased to $102.0 million from $110.3 million. Diluted EPS was $1.33 versus $1.44 a year earlier. Management attributes the decline to lower volume, partially offset by price, productivity initiatives and tight cost control, and reports that gross margin rose 10 basis points to 45.7%. The filing highlights COVID-19 as a significant risk. Management expects second-quarter 2020 sales to be down 15 to 25 percent, several facilities were temporarily closed in China, Italy and India, and the company describes its balance sheet as providing over $1.2 billion of liquidity and gross leverage of 1.5 times. Cash and cash equivalents were $569.2 million at quarter end, and the company drew $150.0 million on its revolving facility, leaving $642.2 million of net available borrowing capacity. Management also reported that it was in compliance with its financial covenants. Capital deployment included the $120.8 million cash acquisition of Flow Management Devices (Flow MD) on February 28, 2020, and $108.9 million of share repurchases of 867 thousand shares. The Board approved an additional $500.0 million repurchase authorization on March 17, 2020, bringing remaining authorization to $713.4 million. Operating cash flow was $84.8 million, and free cash flow, a non-GAAP measure, was $72.0 million.
- 2019-Q3Oct 30, 2019
Idex Quarterly Report for Q3 Ended Sep 30, 2019
IDEX Corporation's Form 10-Q for the quarter ended September 30, 2019 reports third-quarter net sales of $624.2 million, flat versus the prior-year period, with operating income of $141.8 million (down from $145.1 million) and net income of $105.2 million (diluted EPS of $1.37, flat). Management attributes the lower operating income mainly to a $3.3 million fair value inventory step-up charge tied to the Velcora acquisition and higher restructuring expenses of $12.0 million, including a $9.7 million asset impairment in the Health & Science Technologies segment after the company decided to wind down a business that lost its largest customer. Adjusted for those items, the company reports adjusted operating income of $157.1 million and adjusted EPS of $1.52. For the first nine months of 2019, net sales rose to $1,888.6 million and operating income increased to $444.8 million, with net income of $328.7 million and diluted EPS of $4.30. Cash flow from operations was $376.9 million, and cash and cash equivalents were $516.0 million at quarter-end. The company acquired Velcora Holding AB for $87.2 million in cash plus $51.1 million of assumed debt, which was settled on September 3, 2019. A new $800 million revolving credit facility was entered into on May 31, 2019, with no balance outstanding at quarter-end. The filing states that the company was in compliance with its financial covenants, with an interest coverage ratio of 15.96 to 1 and a leverage ratio of 1.24 to 1 against maximums of 3.50 to 1. The company also projected fourth-quarter 2019 EPS of $1.33 to $1.35 and full-year 2019 adjusted EPS of $5.80 to $5.82, with fourth-quarter organic revenue growth expected to be flat.
- 2019-Q2Jul 26, 2019
Idex Quarterly Report for Q2 Ended Jun 30, 2019
IDEX Corporation's Form 10-Q for the quarter ended June 30, 2019 shows second-quarter net sales of $642.1 million, up 1% from $634.4 million a year earlier, with organic sales up 3% partially offset by a 2% unfavorable foreign currency impact. Operating income rose to $155.3 million (24.2% operating margin, versus 23.3% in the prior-year quarter), and net income increased to $113.2 million, or $1.48 diluted EPS, compared with $1.38 a year earlier. For the first six months, net sales were $1.26 billion and net income was $223.5 million, or $2.92 diluted EPS. Cash flow from operations for the six months was $219.8 million, and cash and cash equivalents stood at $543.2 million at June 30, 2019. The balance sheet reflects total assets of $3.64 billion and shareholders' equity of $2.11 billion. Total borrowings were $850.8 million, and the company reported it was in compliance with its financial covenants, with an interest coverage ratio of 15.98 to 1 and a leverage ratio of 1.25 to 1. On May 31, 2019, IDEX entered into a new $800 million revolving credit agreement maturing May 30, 2024, replacing its prior $700 million facility. Adoption of the new lease standard (ASU 2016-02) added right-of-use assets and lease liabilities to the balance sheet, though the company stated it had no material impact on results of operations or cash flows. Looking ahead, management projected third-quarter 2019 EPS of $1.45 to $1.47 and full-year 2019 EPS of $5.78 to $5.85, with third-quarter organic revenue growth of approximately 3% and full-year organic revenue growth of 3% to 4%. Subsequent to the quarter, on July 18, 2019, the company acquired Velcora Holding AB (Roplan and Steridose) for cash consideration of $87.3 million plus $49.9 million of assumed debt, with those businesses having annual revenues of approximately $40.0 million.
- 2019-Q1Apr 26, 2019
Idex Quarterly Report for Q1 Ended Mar 31, 2019
IDEX Corporation's Form 10-Q for the quarter ended March 31, 2019 reports first-quarter net sales of $622.2 million, up from $612.3 million a year earlier, with the filing stating organic sales rose 4% partly offset by a 2% unfavorable foreign currency impact. Operating income was $147.8 million, up from $136.7 million, and operating margin rose to 23.8% from 22.3%. Net income was $110.3 million versus $99.0 million, and diluted EPS was $1.44, up $0.17 or 13% from $1.27. The company reported that restructuring expenses were absent in the quarter compared with $1.6 million a year earlier. Cash flow from operations was $88.7 million, compared with $71.7 million in the prior-year period, and free cash flow (a non-GAAP measure) was $75.8 million. Cash and equivalents totaled $456.1 million, of which $338.7 million was held outside the United States. Total debt was $850.9 million, with the Revolving Facility undrawn and $691.3 million of net available borrowing capacity. The company stated it was in compliance with its financial covenants, with an interest coverage ratio of 15.76 to 1 and a leverage ratio of 1.26 to 1. During the quarter IDEX repurchased 369,810 shares for $51.7 million, leaving $325.3 million of authorization remaining. The filing also projects second-quarter 2019 EPS of $1.47 to $1.50 and full-year 2019 EPS of $5.70 to $5.85, with organic revenue growth of 4% to 5% for both periods. Adoption of ASU 2016-02 (Leases) recognized right-of-use assets and lease liabilities of approximately $68 million, with no material impact on results of operations or cash flows.
- 2018-Q3Oct 24, 2018
Idex Quarterly Report for Q3 Ended Sep 30, 2018
IDEX Corporation's Form 10-Q for the quarter ended September 30, 2018 reports third-quarter net sales of $622.9 million, up 8% from $574.5 million a year earlier, with organic sales up 9%. Operating income rose to $145.1 million (23.3% operating margin, up from 22.0%), and net income increased to $106.4 million, or $1.37 diluted EPS (up $0.29, or 27%). For the nine months, net sales were $1,869.6 million (up 10%), operating income was $429.6 million, and diluted EPS was $4.02. Adjusted EPS for the quarter was $1.41 after $4.6 million of restructuring expenses. The filing states that management projects fourth-quarter 2018 EPS of $1.25 to $1.27 and full-year 2018 adjusted EPS of $5.35 to $5.37, with full-year organic revenue growth of approximately 8%. Balance sheet and cash flow remained solid. Cash and cash equivalents were $491.8 million at September 30, 2018, and total borrowings were $851.3 million, with no balance outstanding under the $700 million Revolving Facility. Operating cash flow for the nine months was $325.8 million, and free cash flow (a non-GAAP measure) was $285.9 million. The company repurchased 357 thousand shares for $51.7 million in the nine months and had $499.3 million of repurchase authorization remaining. The company stated it was in compliance with its interest coverage and leverage covenants. During the quarter, IDEX completed the acquisition of Finger Lakes Instrumentation for an aggregate purchase price of $23.6 million and bought Phantom Controls intellectual property for $4.0 million. The filing also discloses that the Tax Cuts and Jobs Act lowered the effective tax rate to 20.2% for the quarter, and that certain Tax Act accounting elements remain incomplete, including a provisional transition tax obligation of $30.4 million.
- 2018-Q2Jul 25, 2018
Idex Quarterly Report for Q2 Ended Jun 30, 2018
IDEX Corporation's Form 10-Q for the quarter ended June 30, 2018 reports strong second-quarter results. Net sales were $634.4 million, up 11% from $573.4 million in the prior-year quarter, with organic sales up 9%. Operating income rose to $147.8 million (23.3% operating margin) from $125.1 million, and net income increased to $107.1 million from $83.8 million. Diluted EPS was $1.38, up 28%. For the six months, net sales were $1,246.7 million and net income was $206.1 million, with diluted EPS of $2.65. Growth was broad across the Fluid & Metering Technologies, Health & Science Technologies and Fire & Safety/Diversified Products segments, and the company also benefited from lower effective tax rates following the Tax Cuts and Jobs Act, with a second-quarter effective rate of 21.7% versus 26.1% a year earlier. The balance sheet remained solid at June 30, 2018, with cash and cash equivalents of $458.8 million, total borrowings of $861.9 million and shareholders' equity of $1.99 billion. Operating cash flow for the first six months was $192.4 million, and free cash flow (a non-GAAP measure) was $171.5 million. The company repurchased 147 thousand shares for $20.5 million in the first half and paid $61.9 million in dividends. Management reported that it was in compliance with its financial covenants, with an interest coverage ratio of 14.96 to 1 against a 3.0 to 1 minimum and a leverage ratio of 1.34 to 1 against a 3.50 to 1 maximum. Management projected third-quarter 2018 EPS of $1.29 to $1.32 and full-year 2018 adjusted EPS of $5.27 to $5.35, with full-year organic revenue growth of approximately 7%. Subsequent to quarter end, on July 23, 2018, the company acquired Finger Lakes Instrumentation for $20 million in cash plus up to $5 million in earn-out payments, a business with annual revenues of approximately $10 million.
- 2018-Q1Apr 30, 2018
Idex Quarterly Report for Q1 Ended Mar 31, 2018
IDEX Corporation's Form 10-Q for the quarter ended March 31, 2018 reports first-quarter net sales of $612.3 million, up 11% from $553.6 million in the prior-year quarter, with organic sales up 7% and a 4% favorable impact from foreign currency translation. Operating income rose to $136.7 million from $115.7 million, and net income increased to $99.0 million from $75.9 million. Diluted EPS was $1.27 versus $0.99 a year earlier. The filing states that the Fluid & Metering Technologies, Health & Science Technologies and Fire & Safety/Diversified Products segments all grew sales, with Fire & Safety/Diversified Products posting the largest increase at 16%. Cash flow from operations was $71.7 million, down from $85.0 million, which management attributed to higher working capital and higher variable compensation payments. Cash and cash equivalents rose to $413.0 million at March 31, 2018, of which $253.1 million was held outside the United States. Total debt was $860.6 million, and the company stated it was in compliance with its minimum interest coverage ratio of 3.0 to 1 and maximum leverage ratio of 3.50 to 1, with an interest coverage ratio of 14.42 to 1 and a leverage ratio of 1.39 to 1. The company did not repurchase shares in the quarter and had $550.9 million remaining under its repurchase authorization. Management projected second-quarter 2018 EPS of $1.30 to $1.32, full-year 2018 adjusted EPS of $5.05 to $5.20, and second-quarter and full-year organic revenue growth of 5% to 6%. The filing also notes that the company recorded a provisional Tax Act transition tax obligation of $30.4 million, and that its effective tax rate fell to 24.0% from 27.3%.
- 2017-Q3Oct 23, 2017
Idex Quarterly Report for Q3 Ended Sep 30, 2017
IDEX Corporation's Form 10-Q for the quarter ended September 30, 2017 reports third-quarter net sales of $574.5 million, up 8% from $530.4 million a year earlier, with organic sales up 7%. Operating income rose to $126.5 million (22.0% operating margin, versus 20.7%), and net income increased to $83.8 million. Diluted EPS was $1.08, up $0.17 or 19%. For the first nine months, net sales were $1.70 billion, net income was $243.5 million, and diluted EPS was $3.15. Adjusted EPS for the nine months was $3.19, and the company projects full-year 2017 adjusted EPS of $4.25 to $4.27 with fourth-quarter EPS of $1.06 to $1.08. The balance sheet strengthened over the period. Total debt was $879.8 million at September 30, 2017, down from $1.02 billion at year-end 2016, with $29.4 million outstanding on the $700 million revolving facility. Cash and cash equivalents rose to $303.3 million, of which $209.3 million was held outside the United States. Operating cash flow for the nine months was $296.6 million, and free cash flow was $268.5 million. Shareholders' equity grew to $1.81 billion, and the company remained in compliance with its interest coverage and leverage covenants, with a leverage ratio of 1.58 to 1 stated in the filing. Capital deployment in the period included $85.6 million of dividends declared ($1.11 per share), $23.6 million of share repurchases, and $556.4 million of remaining repurchase authorization. There were no acquisitions in the first nine months of 2017, compared with $510.0 million of acquisition spending in the prior-year period. The company recorded $4.8 million of restructuring expenses in the first quarter of 2017, and the filing discloses an ongoing asbestos-related litigation matter that management does not believe will have a material adverse effect.
- 2017-Q2Jul 26, 2017
Idex Quarterly Report for Q2 Ended Jun 30, 2017
IDEX Corporation's second-quarter 2017 Form 10-Q shows net sales of $573.4 million for the three months ended June 30, 2017, up 4% from $549.7 million a year earlier, with organic sales up 3%. Operating income rose to $125.1 million (21.8% operating margin) from $113.8 million, and net income increased 11% to $83.8 million. Diluted EPS was $1.08 versus $0.99. For the six months, net sales were $1.13 billion (up 7%), operating income was $240.8 million (up 11%) after $4.8 million of first-quarter restructuring expenses, and net income was $159.7 million, with diluted EPS of $2.07. Adjusted diluted EPS for the six months was $2.11. The balance sheet strengthened over the period. Total debt fell to $893.8 million from $1.02 billion at December 31, 2016, driven by net revolving facility repayments, and shareholders' equity rose to $1.73 billion from $1.54 billion. Cash and cash equivalents were $218.4 million, of which $171.8 million was held outside the United States. Net cash from operating activities was $172.6 million for the six months, and the company was in compliance with its interest coverage (11.84 to 1) and leverage (1.64 to 1) covenants. Management projects third-quarter 2017 EPS of $1.04 to $1.06 and full-year 2017 adjusted EPS of $4.18 to $4.23. The company disclosed that it acquired SFC Koenig and AWG Fittings in 2016 and divested several product lines, including Hydra-Stop, CVI Japan, IETG and CVI Korea. Share repurchase authorization remaining was $570.2 million, and the company repurchased 106 thousand shares for $9.8 million in the first half of 2017. Management also stated that the company does not believe the asbestos-related lawsuits will have a material adverse effect.
- 2017-Q1Apr 26, 2017
Idex Quarterly Report for Q1 Ended Mar 31, 2017
IDEX Corporation's first-quarter 2017 Form 10-Q reports net sales of $553.6 million, up 10% from $502.6 million in the first quarter of 2016, with organic sales up 5%. Operating income rose to $115.7 million from $103.3 million, and operating margin was 20.9% versus 20.6%. Net income increased to $75.9 million from $68.1 million, and diluted EPS was $0.99 versus $0.89. Results include $4.8 million of restructuring expenses. On an adjusted basis, the company reports adjusted operating income of $120.5 million and adjusted EPS of $1.03. The company also projects second-quarter 2017 EPS of $1.04 to $1.06 and full-year 2017 adjusted EPS of $4.00 to $4.10. Cash flow from operations was $85.0 million, up from $70.4 million, and free cash flow was $74.8 million. Cash and equivalents were $216.1 million at March 31, 2017, and total borrowings were $955.9 million, including $105.3 million under the $700 million Revolving Facility. The company stated it was in compliance with its interest coverage and leverage covenants, with an interest coverage ratio of 11.65 to 1 and a leverage ratio of 1.78 to 1. Shareholders' equity rose to $1.64 billion, and the company repurchased 82,000 shares for $7.6 million during the quarter. The filing also shows acquisition-driven growth. Fire & Safety/Diversified Products sales rose 31%, reflecting the Akron Brass and AWG Fittings acquisitions, and the company early adopted ASU 2017-07 on pension cost presentation. Management noted that the most significant potential change from the pending ASU 2014-09 revenue standard relates to customized product contracts in the Health & Science Technologies segment, which it expects to remain substantially unchanged.
- 2016-Q3Oct 25, 2016
Idex Quarterly Report for Q3 Ended Sep 30, 2016
IDEX Corporation's third-quarter 2016 Form 10-Q reports net sales of $530.4 million for the three months ended September 30, 2016, up 5% from $503.8 million a year earlier, while organic sales were down 2%. Operating income fell to $108.9 million from $121.8 million, and net income decreased to $69.9 million from $79.5 million; diluted EPS was $0.91 versus $1.02. For the nine months, net sales were $1.58 billion, operating income was $324.4 million, and net income was $213.8 million, with diluted EPS of $2.78. The decline in operating income was driven mainly by a $2.1 million loss on sale of businesses in 2016 versus an $18.1 million gain in 2015, plus fair value inventory step-up charges tied to 2016 acquisitions. Growth was acquisition-driven. The company acquired Akron Brass ($221.4 million), AWG Fittings ($47.5 million) and SFC Koenig ($241.1 million) in 2016, for total cash consideration of $510.0 million, and it divested Hydra-Stop and Melles Griot KK. Total borrowings rose to $1.11 billion at September 30, 2016, including $200 million of new 3.20% and 3.37% Senior Notes issued in June 2016, and the Revolving Facility balance was $255.1 million with about $436.7 million of net available capacity. The company was in compliance with its covenants, reporting an interest coverage ratio of 12.25 to 1 and a leverage ratio of 1.98 to 1. Cash and equivalents were $239.4 million, and the company repurchased $55.0 million of stock in the first nine months with $580.0 million of authorization remaining. Management projects fourth-quarter 2016 adjusted EPS of $0.92 to $0.94 and full-year 2016 adjusted EPS of $3.72 to $3.74, with full-year revenue growth of 5% and full-year organic revenue of negative 1%. The filing also notes a pending pension lump-sum offering expected to produce a pre-tax settlement loss of $3.0 million to $6.0 million in the fourth quarter, and a subsequent event in which the company sold its IETG and 40Seven subsidiaries for $2.8 million in October 2016.
- 2016-Q2Aug 1, 2016
Idex Quarterly Report for Q2 Ended Jun 30, 2016
IDEX Corporation's second-quarter 2016 Form 10-Q reports net sales of $549.7 million for the three months ended June 30, 2016, up 7% from the prior year, with organic sales down 1%. Operating income was $113.0 million, up 3%, and net income rose 9% to $75.8 million, or $0.99 diluted EPS. For the six months, net sales were $1.05 billion (up 3%, organic down 2%), operating income was $215.5 million, and net income was $143.9 million. Growth was driven mainly by acquisitions, including Akron Brass in March 2016 for $221.6 million in cash, while operating margin declined to 20.6% from 21.3% in the quarter, largely due to a $3.6 million inventory step-up charge tied to Akron Brass. The balance sheet expanded as the company funded acquisitions and repurchases with debt. Long-term borrowings rose to $1.05 billion from $839.7 million at year-end 2015, following the June 13, 2016 private placement of $100 million 3.20% Senior Notes due 2023 and $100 million 3.37% Senior Notes due 2025. The Revolving Facility balance was $210.0 million at June 30, 2016, with net available borrowing capacity of about $482.1 million. The company reported an interest coverage ratio of 12.49 to 1 and a leverage ratio of 1.97 to 1, both within its covenants of at least 3.0 to 1 and at most 3.50 to 1. Management guided third-quarter 2016 EPS to $0.90 to $0.92 and full-year 2016 EPS to $3.70 to $3.75, assuming flat organic growth and an operating margin of 20.5% to 21.0%. Subsequent events include the announced acquisition of AWG Fittings (about $51 million), a definitive agreement to acquire SFC-Koenig for an enterprise value of about $240 million, and agreements to sell Melles Griot KK (about $19 million) and the Hydra-Stop product line ($15 million cash plus up to $2 million contingent consideration).
- 2016-Q1Apr 25, 2016
Idex Quarterly Report for Q1 Ended Mar 31, 2016
IDEX Corporation's first-quarter 2016 Form 10-Q shows flat net sales of $502.6 million versus $502.2 million a year earlier, with organic sales down 3% excluding acquisitions and currency translation. Operating income rose to $102.6 million from $101.8 million, and net income increased to $68.1 million from $66.0 million. Diluted EPS was $0.89 compared with $0.84 in the prior-year quarter. The filing notes that the increase in operating income primarily reflected a reversal of contingent consideration tied to a 2015 acquisition, partly offset by an inventory step-up charge related to the Akron Brass acquisition. Management projects second-quarter 2016 EPS of $0.91 to $0.93 and full-year 2016 EPS of $3.70 to $3.75. The company's balance sheet grew substantially during the quarter, with total assets rising to $3.14 billion from $2.81 billion at year-end 2015. This was driven by the $221.6 million cash acquisition of Akron Brass, funded with borrowings under the Revolving Facility. Total borrowings increased to $1.10 billion, of which $450.0 million was drawn on the $700 million Revolving Facility, leaving approximately $242.4 million of net available borrowing capacity. Cash from operating activities rose to $70.4 million from $49.4 million. The company repurchased 628 thousand shares for $45.8 million during the quarter, and $589.2 million remained under its repurchase authorization. Segment results were mixed. Fluid & Metering Technologies sales fell 3% and operating income declined to $51.4 million, while Health & Science Technologies sales rose 4% and operating income increased to $40.7 million. Fire & Safety/Diversified Products operating income declined to $25.4 million, which the filing attributes entirely to the Akron Brass acquisition. The company reported it was in compliance with its revolving facility financial covenants, with an interest coverage ratio of 12.38 to 1 and a leverage ratio of 2.04 to 1.
- 2015-Q3Oct 27, 2015
Idex Quarterly Report for Q3 Ended Sep 30, 2015
IDEX Corporation's third-quarter 2015 Form 10-Q shows net sales of $503.8 million for the three months ended September 30, 2015, a 6% decrease from the prior year, with organic sales down 4%. Operating income rose to $121.8 million (24.2% operating margin) from $110.8 million, but this was driven by an $18.1 million pre-tax gain on the sale of the Ismatec product line. Excluding that gain and $4.7 million of restructuring expenses, adjusted operating income was $108.5 million, down 2%. Diluted EPS was $1.02, up 16%, while adjusted EPS was $0.89, up 1%. For the nine months, net sales were $1.52 billion, down 6%, with organic sales down 3%, and net income of $215.0 million was down 1%. The company deployed capital into acquisitions during 2015. Novotema ($61.1 million), Alfa Valvole ($112.6 million) and CiDRA Precision Services ($24.2 million aggregate) were acquired, with total acquisition cash outflows of $193.2 million for the nine months. IDEX also paid off its 2.58% Senior Euro Notes ($88.4 million) and entered a new $700 million revolving credit facility maturing June 2020, with $203.0 million outstanding at September 30, 2015. Cash and equivalents fell to $306.5 million, of which $270.0 million was held outside the United States. The company repurchased 2.4 million shares for $179.4 million during the nine months and had $366.0 million of repurchase authorization remaining. Management guided to fourth-quarter 2015 adjusted EPS of $0.88 to $0.91 and full-year 2015 adjusted EPS of $3.50 to $3.53, anticipating full-year organic sales down 2% to 3%. Legal proceedings include asbestos-related claims against the company and four subsidiaries, which management does not believe will have a material adverse effect, with insurance covering most settlements to date.
- 2015-Q2Jul 27, 2015
Idex Quarterly Report for Q2 Ended Jun 30, 2015
IDEX Corporation reported lower second-quarter 2015 results, with net sales of $514.9 million, down 6%, and organic sales down 2%, excluding acquisitions and foreign currency translation. Operating income was $109.9 million, down 2%, and net income was $69.6 million, down 3%. Diluted EPS rose 1 cent to $0.89. For the six months, sales were $1,017.1 million, down 7%, and diluted EPS was $1.72, down 7 cents. The filing attributes the weakness to depressed oil prices, softer North American industrial distribution, and lower volume in the Fire & Safety/Diversified Products segment, where sales fell 18% in the quarter. Gross margin improved to 45.0% from 44.1% in the quarter, which the company attributed to productivity and prior-year restructuring benefits. The company continued its acquisition activity in the second quarter. It acquired Novotema, SpA for about $60.7 million and Alfa Valvole, S.r.l. for $112.6 million, both funded with cash on hand. On June 23, 2015, it entered into a new $700 million revolving credit agreement maturing in June 2020, replacing the 2011 facility. Cash and cash equivalents fell to $311.5 million from $509.1 million at year-end 2014, and total borrowings were $875.2 million, including $225.0 million drawn on the revolver. Cash flow from operations was $148.4 million for the six months, down from $166.2 million. The company repurchased 1.5 million shares for $113.3 million during the six months and had $432.2 million remaining under its repurchase authorization. Management projects third-quarter 2015 diluted EPS of $0.88 to $0.90 and full-year 2015 diluted EPS of $3.50 to $3.60. The company also announced additional restructuring actions in the second half of 2015, with expense not expected to exceed $8 million, and a July 2015 acquisition of CiDRA Precision Services, LLC for about $19.5 million in cash plus an earn-out of up to $5.5 million.
- 2015-Q1Apr 28, 2015
Idex Quarterly Report for Q1 Ended Mar 31, 2015
IDEX Corporation's first-quarter 2015 Form 10-Q reports net sales of $502.2 million, down 8% from $544.0 million a year earlier, with organic sales down 4% and a 4% unfavorable foreign currency translation effect. Operating income fell to $101.8 million from $113.8 million, and net income decreased to $66.0 million from $74.5 million. Diluted EPS was $0.84 versus $0.91 a year earlier. The filing attributes the decline mainly to lower volume, partly offset by productivity gains and benefits from 2014 restructuring actions. Gross margin was essentially stable at 45.0% versus 44.9%. Operating cash flow fell to $49.4 million from $74.2 million, reflecting severance payments, the timing of pension plan payments, and lower earnings. The Fire & Safety/Diversified Products segment was the weakest, with sales down 22% and operating income down to $27.2 million from $39.6 million. Balance sheet and capital allocation activity was active during the quarter. Total borrowings rose to $908.2 million, with the Revolving Facility drawn to $170.0 million, and the company held $494.5 million of cash, of which $391.2 million was outside the United States. The company repurchased 829,744 shares for $62.1 million, leaving $483.3 million of repurchase authorization. Subsequent to quarter-end, IDEX agreed on April 20, 2015 to acquire Novotema, SpA for approximately $61 million (€57 million), and management projected second-quarter 2015 diluted EPS of $0.88 to $0.90 and full-year 2015 diluted EPS of $3.50 to $3.60. Goodwill declined to $1.29 billion, mainly from foreign currency translation, and the company disclosed that the IOP reporting unit's fair value was approximately 15% above carrying value at its October 31, 2014 impairment test. The company stated it was in compliance with its financial covenants, reporting an interest coverage ratio of 12.39 to 1 and a leverage ratio of 1.82 to 1 against required levels of 3.0 to 1 and 3.25 to 1.
- 2014-Q3Oct 27, 2014
Idex Quarterly Report for Q3 Ended Sep 30, 2014
IDEX Corporation's Form 10-Q for the quarter ended September 30, 2014 shows continued growth in the third quarter. Net sales were $533.2 million, up from $490.6 million a year earlier, and operating income rose to $110.8 million from $97.4 million. Net income increased to $71.4 million, and diluted EPS was $0.88 versus $0.78 in the prior-year quarter. For the first nine months, net sales reached $1,623.9 million and net income was $217.8 million, with diluted EPS of $2.68. The filing attributes the growth to a 7% increase in organic sales for the quarter, with acquisitions (Aegis, acquired April 2014) and favorable foreign currency translation contributing the balance. The Fire & Safety/Diversified Products segment was the standout, with third-quarter operating income of $31.4 million and operating margin of 26.1%. Balance sheet and cash flow data show cash and equivalents of $487.1 million, total borrowings of $823.4 million, and shareholders' equity of $1,587.9 million at September 30, 2014. Net cash from operating activities for the first nine months was $266.6 million, down from $299.9 million in the prior-year period, which the company attributed to higher federal income tax payments and higher working capital needs. The company repurchased 2.0 million shares for $149.7 million during the first nine months, leaving $218.2 million of repurchase authorization. Management projected full-year 2014 diluted EPS of $3.52 to $3.55, based on 5-6% organic revenue growth expectations. The filing reports that the company is in compliance with its financial covenants, with an interest coverage ratio of 12.94 to 1 against a 3.0 to 1 minimum and a leverage ratio of 1.58 to 1 against a 3.25 to 1 maximum. A $70.0 million balance was outstanding under the $700.0 million revolving facility, which had approximately $621.7 million of net available capacity. The company also disclosed that it is a defendant in asbestos-related personal injury lawsuits, for which it has not recorded a material provision and which it does not believe will have a material adverse effect.
- 2014-Q2Jul 29, 2014
Idex Quarterly Report for Q2 Ended Jun 30, 2014
IDEX Corporation's Form 10-Q for the quarter ended June 30, 2014 reports second-quarter net sales of $546.7 million, up 5% from $518.4 million a year earlier, with organic sales up 4%. Operating income rose 13% to $112.1 million, and net income increased 15% to $71.8 million, or diluted EPS of $0.88 (up 16%). For the first six months, net sales were $1,090.7 million (up 8%), operating income was $225.9 million (up 16%), and net income was $146.3 million (up 18%), with diluted EPS of $1.79 (up 20%). Gross margin improved to 44.1% in the quarter from 43.0%, attributed to volume leverage and productivity. Management projects third-quarter 2014 diluted EPS of $0.83 to $0.85 and has raised its full-year 2014 diluted EPS outlook to $3.50 to $3.55, based on projected 5-6% organic revenue growth. Segment results were mixed: Fire & Safety/Diversified Products grew sales 19% in the quarter, while Fluid & Metering Technologies sales were roughly flat at $226.1 million, with operating margin down slightly due to acquisition-related charges. The balance sheet remained solid, with cash of $485.3 million, total borrowings of $816.9 million, and $637.2 million of net available capacity under the $700.0 million Revolving Facility. The company acquired Aegis Flow Technologies for about $26 million in April 2014 and repurchased 1.2 million shares for $85.7 million in the first half, with $282.2 million of board authorization remaining. The $110.5 million 2.58% Senior Euro Notes mature in June 2015 and are classified as current.
- 2014-Q1Apr 29, 2014
Idex Quarterly Report for Q1 Ended Mar 31, 2014
IDEX Corporation's first-quarter 2014 Form 10-Q reports net sales of $544.0 million, up 10% from $494.4 million a year earlier, with organic sales up 8%. Operating income rose to $113.8 million from $94.7 million, and net income increased 22% to $74.5 million. Diluted EPS was $0.91, up 17 cents, or 23%, from $0.74. Gross margin improved to 44.9% from 42.9%, driven by volume and prior structural cost actions. Operating cash flow was $74.2 million and capital expenditures were $10.8 million. All three segments grew sales. Fire & Safety/Diversified Products rose 23% to $137.3 million, largely on a large Dispensing order, while Health & Science Technologies grew 8% and Fluid & Metering Technologies grew 6%. Operating margin for the company reached 20.9%, up from 19.2%. Management projects second-quarter 2014 EPS of $0.85 to $0.87 and has raised its full-year 2014 diluted EPS outlook to $3.38 to $3.45, citing projected 4-5% organic revenue growth. Balance sheet items include cash of $458.4 million, total debt of $780.2 million, and $675.1 million of net available capacity under the $700.0 million Revolving Facility. The company was in compliance with its financial covenants, with an interest coverage ratio of 12.20 to 1 and a leverage ratio of 1.58 to 1. Shares repurchased in the quarter totaled 0.6 million at a cost of $40.1 million, leaving $327.8 million available under repurchase authorizations. On April 28, 2014, the company acquired Aegis Flow Technologies for approximately $26.0 million in cash.
- 2013-Q3Oct 31, 2013
Idex Quarterly Report for Q3 Ended Sep 30, 2013
IDEX Corporation's third-quarter 2013 Form 10-Q, filed October 31, 2013, reports net sales of $490.6 million for the three months ended September 30, 2013, up 2% from $479.9 million a year earlier, with organic sales up 1% and acquisitions contributing 1%. Operating income rose to $97.4 million from $80.6 million, with operating margin of 19.8% versus 16.8%, helped by volume, productivity and prior-year restructuring benefits. Net income increased 27% to $63.8 million, and diluted EPS was $0.78 versus $0.60, up 30%. The company notes that the third quarter of 2012 included $7.1 million of restructuring charges, which did not recur in 2013. For the first nine months of 2013, net sales were $1,503.5 million, up 3%, and net income was $187.7 million, up 20%. Diluted EPS was $2.27, up 21%. Operating cash flow rose to $299.9 million from $240.5 million, supporting $139.9 million of share repurchases during the period. Management raised its full-year 2013 diluted EPS outlook to $3.05 to $3.07 and projects fourth-quarter EPS of $0.78 to $0.80, assuming 2% organic revenue growth for the year. Balance sheet strength is reflected in cash and equivalents of $399.8 million and total borrowings of $784.4 million, with $670.9 million of net available capacity under the $700.0 million Revolving Facility. The company states it was in compliance with its financial covenants, with an interest coverage ratio of 11.05 to 1 and a leverage ratio of 1.75 to 1, against required minimums of 3.0 to 1 and maximums of 3.25 to 1.
- 2013-Q2Aug 5, 2013
Idex Quarterly Report for Q2 Ended Jun 30, 2013
IDEX Corporation's Form 10-Q for the quarter ended June 30, 2013, filed August 5, 2013, reports second-quarter net sales of $518.4 million, up from $494.1 million in the prior-year quarter, with operating income of $99.6 million versus $88.7 million and diluted EPS of $0.76 versus $0.65. For the first six months, net sales were $1,012.9 million and net income was $123.9 million, compared with $106.5 million a year earlier. Diluted EPS for the six months was $1.49. The filing states that organic sales were flat for the six months, while acquisitions (ERC, Matcon and FTL) drove most of the sales growth. Management raised its full-year 2013 diluted EPS outlook to $2.93 to $2.98 and projected third-quarter 2013 EPS of $0.72 to $0.74. The balance sheet remained solid at June 30, 2013, with cash and cash equivalents of $374.5 million, total assets of $2.83 billion and shareholders' equity of $1.48 billion. Total borrowings were $815.5 million, and the filing reports $55.0 million outstanding under the $700.0 million Revolving Facility, with approximately $635.3 million of net available borrowing capacity. The company was in compliance with its financial covenants, with an interest coverage ratio of 10.66 to 1 and a leverage ratio of 1.88 to 1 against required levels of 3.0 to 1 and 3.25 to 1. During the first six months, IDEX repurchased 1.6 million shares for $86.7 million and had $148.7 million remaining under its October 2012 repurchase authorization. Operating cash flow rose to $181.5 million from $139.5 million. IDEX reports three segments: Fluid & Metering Technologies, Health & Science Technologies, and Fire & Safety/Diversified Products. Fluid & Metering led operating income in the second quarter with $56.1 million, and its operating margin was 24.9%. Management described the company's legal exposure, including asbestos-related lawsuits, as not expected to have a material adverse effect.
- 2013-Q1May 6, 2013
Idex Quarterly Report for Q1 Ended Mar 31, 2013
IDEX Corporation's first-quarter 2013 Form 10-Q, filed May 2013, reports net sales of $494.4 million, up 1% from $489.4 million in the first quarter of 2012, while organic sales declined 1%. Operating income rose to $94.7 million from $84.6 million, and net income increased to $61.3 million from $52.2 million, or diluted EPS of $0.74 versus $0.62. The filing attributes the margin improvement to higher volume, productivity gains, structural cost actions taken in prior years, and the absence of 2012 restructuring charges of $4.9 million. Management characterized North America as improving, Europe as soft and Asia as uneven, and forecast second-quarter EPS of $0.73 to $0.75 and full-year EPS of $2.85 to $2.95. The balance sheet remained solid, with cash and cash equivalents of $341.0 million, total debt of $822.3 million, and shareholders' equity of $1.48 billion at March 31, 2013. Operating cash flow was $72.2 million, up from $58.7 million, and the company spent $34.6 million to acquire FTL Seals Technology and repurchased 0.7 million shares for $35.7 million. Net available capacity under the $700.0 million revolving facility was approximately $631.2 million, and the company stated it was in compliance with its financial covenants. The Health & Science Technologies segment was the weak spot, with organic sales down 7%, while Fire & Safety/Diversified Products grew 7% organically. The company reported no material impact from pending legal proceedings, including asbestos-related claims that it does not believe will have a material adverse effect.
- 2012-Q3Nov 2, 2012
Idex Quarterly Report for Q3 Ended Sep 30, 2012
IDEX Corporation reported third-quarter 2012 net sales of $479.9 million, up 1% from $476.9 million a year earlier, and net income of $50.1 million, compared with $48.3 million. Diluted EPS was $0.60, up $0.02, or 3%. For the nine months ended September 30, 2012, net sales were $1,463.4 million, up 8%, with organic sales up 4%. Operating income rose 11% to $253.8 million, net income increased 7% to $156.6 million, and diluted EPS was $1.87, up 12 cents. Management attributed the year-to-date gains to volume leverage, productivity, and acquisitions, while noting weak market conditions outside the U.S. Management expects fourth-quarter organic revenue to be flat compared with the fourth quarter of 2011 and maintained its full-year 2012 adjusted EPS guidance of $2.65 to $2.70. Operating cash flow for the nine months was $240.5 million, up from $175.6 million. Cash and cash equivalents were $260.5 million and total debt was $787.9 million. The company was in compliance with its financial covenants, reporting an interest coverage ratio of 10.6 to 1 against a minimum of 3.0 to 1 and a leverage ratio of 1.9 to 1 against a maximum of 3.25 to 1. During the nine months, IDEX acquired PPC, ERC and Matcon, and repurchased 1.9 million shares for $75.2 million. On October 22, 2012, the Board increased the repurchase authorization by $200.0 million, bringing the total authorized amount to $250.0 million. Restructuring expenses were $14.6 million for the nine months. The company reported no material adverse effect expected from its ordinary-course litigation, including asbestos-related claims.
- 2012-Q2Aug 1, 2012
Idex Quarterly Report for Q2 Ended Jun 30, 2012
IDEX Corporation's Form 10-Q for the quarter ended June 30, 2012 shows second-quarter net sales of $494.1 million, up from $453.8 million a year earlier, with operating income of $88.7 million and diluted EPS of $0.65 versus $0.60. For the six months, net sales were $983.6 million and diluted EPS was $1.27, compared with $1.17 in 2011. The filing states sales rose 12% for the six months, with organic sales up 6%, and that operating income rose 10% to $173.2 million, while net income rose 9% to $106.5 million. Management revised its full-year 2012 outlook downward, now expecting diluted EPS of $2.65 to $2.70, excluding future restructuring charges and the impact of the recently announced Matcon acquisition. Projected third-quarter 2012 EPS is $0.62 to $0.64. The company cited a challenging economic environment and said the Optics & Photonics platform sales were below expectations due to weak defense, biotech and electronics demand. Restructuring expenses totaled $7.5 million for the first six months. Balance sheet and cash flow are solid. Cash flow from operating activities was $139.5 million for the six months, up $58.6 million from 2011. Total borrowings were $759.3 million, the $700.0 million Revolving Facility was undrawn at June 30, 2012, and the company stated it was in compliance with its financial covenants. The company repurchased 0.9 million shares for about $36.0 million during the six months. After the quarter, on July 20, 2012, it acquired Matcon Group Limited for about $37.5 million in cash plus potential contingent payments.
- 2012-Q1May 8, 2012
Idex Quarterly Report for Q1 Ended Mar 31, 2012
IDEX Corporation's Form 10-Q for the quarter ended March 31, 2012 reports net sales of $489.4 million, up 15% from $427.1 million a year earlier. The filing attributes the increase to 6% organic sales growth, 10% from acquisitions (AT Films, Microfluidics and CVI MG) and a 1% unfavorable foreign currency translation effect. Operating income rose to $84.6 million from $77.7 million, but operating margin declined to 17.3% from 18.2%, which the company attributes mainly to restructuring charges and the dilutive effect of acquisitions. Net income increased to $52.2 million from $48.0 million, and diluted earnings per share were $0.62 compared with $0.57. Gross margin was 41.5% versus 41.8%, reflecting product mix. Cash flow from operations increased to $58.7 million from $29.1 million, which the company attributes mainly to higher volume. At quarter end the company held $245.5 million of cash and cash equivalents and $773.6 million of total debt. Interest expense rose to $10.7 million from $6.5 million, reflecting debt issued for the CVI MG acquisition and higher rates on fixed-rate debt. The company reported it was in compliance with its financial covenants, with an interest coverage ratio of 11.8 to 1 and a leverage ratio of 2.0 to 1. Net available capacity under the $700.0 million Revolving Facility was approximately $681.8 million. Subsequent to quarter end, IDEX acquired Precision Photonics Corporation for approximately $20.5 million on April 11, 2012, and ERC for approximately $20.0 million on April 30, 2012. The company also recorded $4.9 million of pre-tax restructuring expenses in the quarter, and it repurchased 239,185 shares in February 2012 under a $125.0 million total repurchase authorization. The filing states that the company is a named defendant with seven subsidiaries in asbestos-related lawsuits and does not currently believe these claims will have a material adverse effect.
- 2011-Q3Oct 31, 2011
Idex Quarterly Report for Q3 Ended Sep 30, 2011
IDEX Corporation's Form 10-Q for the quarter ended September 30, 2011 shows a strong third quarter and nine months, driven by sales growth and acquisitions. Net sales for the three months ended September 30, 2011 were $476.9 million, up from $373.7 million in 2010, and the filing attributes the 28% increase to 9% organic growth, 16% from acquisitions and 3% favorable currency translation. Net income for the quarter rose to $48.3 million from $38.6 million, and diluted EPS was $0.58 versus $0.47. For the nine months, net sales were $1,357.8 million and net income was $146.5 million, with diluted EPS of $1.75. The largest event of the period was the June 2011 acquisition of CVI Melles Griot for $397.1 million, with about $365.0 million of the cash price financed through the revolving credit facility. Acquisitions of AT Films and Microfluidics were also completed in the first half of 2011. Total debt rose to $818.6 million at September 30, 2011, from $527.9 million at December 31, 2010, and interest expense increased to $7.8 million for the quarter from $4.2 million a year earlier. The company also recorded a $12.8 million acquisition fair value inventory charge in cost of sales for the quarter, which reduced operating margin to 15.0% from 16.7%. The company entered into a new $700.0 million revolving credit facility on June 27, 2011, maturing in 2016, with $320.9 million outstanding at quarter end. Management states it is in compliance with its financial covenants and believes cash flow from operations will fund operating needs, capital expenditures, interest and dividends through 2012. A restructuring initiative in the third quarter of 2011 resulted in $2.9 million of pre-tax expense, and the filing states that legal proceedings, including asbestos-related claims, are not expected to have a material adverse effect.
- 2011-Q2Aug 8, 2011
Idex Quarterly Report for Q2 Ended Jun 30, 2011
IDEX Corporation's second-quarter 2011 Form 10-Q reports net sales of $453.8 million for the three months ended June 30, 2011, up 20% from $378.5 million a year earlier, with organic sales up 8%, acquisitions contributing 8% and favorable foreign currency translation contributing 4%. Net income rose to $50.2 million from $40.4 million, and diluted EPS was $0.60 versus $0.49. For the six months, net sales were $880.9 million and net income was $98.1 million, with diluted EPS of $1.17 versus $0.94. Operating margin was 17.5% for the quarter, up from 16.6%, helped by volume and a $2.8 million gain on the sale of a facility in Italy, partly offset by acquisition-related costs and an inventory fair value charge. The quarter was dominated by acquisitions. IDEX completed CVI Melles Griot on June 10, 2011 for an aggregate purchase price of $397.1 million, financed largely by $365.0 million of revolving credit borrowings, and also bought Microfluidics ($18.5 million) and AT Films ($34.5 million) earlier in 2011. Total borrowings rose to $878.1 million at June 30, 2011 from $527.9 million at year-end 2010, and interest expense more than doubled to $13.2 million for the six months. On June 27, 2011 the company entered into a new $700.0 million revolving credit facility maturing in 2016, replacing its prior $600.0 million facility, and it reported $374.2 million outstanding under that facility at quarter-end. The company stated it was in compliance with its financial covenants. Other items include a $350.0 million forward-starting interest rate contract entered on July 12, 2011 in anticipation of new debt issuance in the third quarter, and a change in Chief Executive Officer: Andrew K. Silvernail replaced Lawrence D. Kingsley effective August 10, 2011. Operating cash flow fell to $80.8 million for the six months from $95.7 million, mainly due to higher working capital requirements.
- 2011-Q1May 3, 2011
Idex Quarterly Report for Q1 Ended Mar 31, 2011
IDEX Corporation's first-quarter 2011 Form 10-Q, filed May 3, 2011, reports net sales of $427.1 million, up 20% from $355.6 million in the first quarter of 2010. The filing attributes the increase to 12% organic growth, 7% from acquisitions and 1% favorable foreign currency translation. Operating income rose to $77.7 million (18.2% operating margin) from $57.9 million (16.3%), and net income was $48.0 million, or $0.57 per diluted share, compared with $36.6 million, or $0.45 per diluted share, a year earlier. Health & Science Technologies grew the fastest, with sales up 43% to $133.6 million, while Dispensing Equipment declined 4% to $32.2 million. The balance sheet expanded with acquisitions. Goodwill rose to $1.25 billion and total assets reached $2.47 billion. The company completed two acquisitions in the quarter, Advanced Thin Films (AT Films) for $34.5 million in aggregate and Microfluidics for $18.6 million in cash, and spent $50.4 million on acquisitions net of cash acquired. Cash fell to $195.5 million from $235.1 million at year-end 2010. Total borrowings were $518.2 million, of which $102.8 million was current, largely because the $600.0 million Credit Facility and the $82.0 million Term Loan both mature on December 21, 2011. Management said it intends to enter a new revolving credit facility in 2011. The filing reports that the company was in compliance with its financial covenants at March 31, 2011. Cash flow from operations was $29.1 million, and capital expenditures were $11.4 million. The company also disclosed asbestos-related lawsuits naming the company and eight subsidiaries, which it does not believe will have a material adverse effect.
- 2010-Q3Nov 4, 2010
Idex Quarterly Report for Q3 Ended Sep 30, 2010
IDEX Corporation's third-quarter 2010 Form 10-Q, filed November 4, 2010, shows net sales of $373.7 million for the quarter, up 16% from the prior-year period, driven by a 14% increase in organic sales and 4% from the Seals and OBL acquisitions, partly offset by 2% from unfavorable foreign currency translation. Operating income rose to $62.4 million (16.7% operating margin) from $46.5 million (14.4%), and net income was $38.6 million, or $0.47 per diluted share, compared with $29.8 million, or $0.37, a year earlier. For the nine months, net sales were $1,107.9 million, up 12%, and diluted EPS was $1.40, up 41%. The balance sheet expanded in 2010 mainly through acquisitions and borrowing. Total assets were $2.35 billion at September 30, 2010, versus $2.10 billion at December 31, 2009, and total borrowings rose to $491.6 million from $400.1 million, including a June 2010 private placement of 2.58% Senior Notes. Operating cash flow of $157.3 million for the nine months was flat year over year, and cash and equivalents increased to $206.1 million. The company also entered into a $300.0 million forward setting interest rate contract to lock in rates ahead of expected fourth-quarter 2010 debt issuance. Management highlighted strong growth in Health & Science Technologies (sales up 37% in the quarter) and Fluid & Metering Technologies, with restructuring expenses of $3.5 million in the quarter under the 2009 initiative. The filing notes three acquisitions in 2010 (Seals, OBL and Periflo), which management does not consider material, and a subsequent event: the November 1, 2010 acquisition of The Fitzpatrick Company for about $21.0 million in cash. Legal matters, including asbestos-related claims, are not expected to have a material adverse effect.
- 2010-Q2Aug 6, 2010
Idex Quarterly Report for Q2 Ended Jun 30, 2010
IDEX Corporation's Form 10-Q for the quarter ended June 30, 2010 reports second-quarter net sales of $378.5 million, up from $336.5 million a year earlier, with net income of $40.4 million, or $0.49 diluted earnings per share, compared with $27.9 million and $0.34 in the second quarter of 2009. For the first six months, net sales were $734.1 million and net income was $77.0 million, or $0.94 per diluted share. Management attributes the sales increase to an 11% rise in organic sales for the quarter, 3% from the April 2010 acquisition of Seals, Ltd., and a 1% unfavorable currency effect. Operating margin widened to 16.6% in the quarter from 13.9% a year earlier, reflecting higher volume and restructuring-related cost reductions. Gross margin rose to 40.9% from 39.0%. The balance sheet shows total assets of $2.21 billion and total borrowings of $470.4 million at June 30, 2010, up from $400.1 million at year-end 2009. The increase came largely from the $51.3 million cash payment for Seals and a June 2010 private placement of 2.58% Senior Notes due 2015 (€81.0 million, or $96.8 million). Cash and cash equivalents rose to $159.1 million from $73.5 million, and operating cash flow for the six months was $95.7 million. The company also entered into a $300.0 million forward-setting interest rate contract to lock in rates for anticipated fourth-quarter 2010 debt issuance. A subsequent event was the July 21, 2010 acquisition of OBL, S.r.l. for approximately $16.8 million in cash. The filing discloses ongoing asbestos-related lawsuits against the company and six subsidiaries, which management does not currently believe will have a material adverse effect, and it reports that $75.0 million remained available under the company's share repurchase authorization at June 30, 2010.